- Sell-side analysts comment on cancer therapy data to be presented at ESMO in Barcelona starting today.
- SVB Leerink's Andrew Berens says Seattle Genetics (NASDAQ:SGEN) may see a spike in buying on positive results for enfortumab vedotin (combined with Merck's Keytruda in first-line bladder cancer) and tucatinib. The antibody-drug conjugate/Keytruda combo showed a 62% response rate, including a 14% complete response rate, with a favorable safety profile.
- He says Clovis Oncology's (NASDAQ:CLVS) data in BRCA-positive patients is "largely in-line" with expectations, adding that investors "are likely to remain cautious" considering competition from AstraZeneca (NYSE:AZN) and Merck (NYSE:MRK) and GlaxoSmithKline (NYSE:GSK) in prostate and ovarian cancer.
- Stifel's Stephen Willey cites encouraging data from X4 Pharmaceuticals (NASDAQ:XFOR), Zymeworks (NYSE:ZYME) and MacroGenics (NASDAQ:MGNX).
- Piper's Joseph Catanzaro likes Amgen (NASDAQ:AMGN), citing updated data on AMG 510. He is unimpressed with ImmunoGen's (NASDAQ:IMGN) mirvetuximab triplet therapy data, regarding it as "undifferentiated" from standard of care.
- Goldman's Salveen Richter is bullish on SGEN as well saying that enfortumab vedotin should receive the FDA nod in March 2020.